Encouraging Phase II data supports broad therapeutic potential of eftilagimod alpha in non-small cell lung cancer (NSCLC), head & neck squamous cell cancer (HNSCC) and metastatic breast cancer (MBC) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback